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Prognostic factors in diffuse proliferative lupus glomerulonephritis. A
number of clinical laboratory and biopsy-derived parameters were
assessed for their prognostic significance in the short (24 months),
intermediate (60 months) and long terms in 45 patients (43 female, 2
male) with diffuse proliferative lupus glomerulonephritis (DPGN). The
factors evaluated were serum creatinine (Scr) and urinary protein at
time of biopsy, initial dose of prednisone and immunosuppressive after
biopsy, activity index (Al), chronicity index (CI), their individual
components, extent of extraglomerular (tubulo-interstitial) immune
deposits (EGD) and mean number of intraglomerular monocytes per
glomerulus (NSE index). Using proportional hazards analysis to eval-
uate the parameters, Scr (P = 0.003), Al (P = 0.005) and NSE index (P
= 0.038) were shown to be significant predictors of outcome when all
variables except the components of Al and CI were considered. When
Al and CI were omitted but their components included, Sr (P =
0.0005), NSE index (P = 0.024), extent of karyorrhexis (P = 0.035) and
glomerulosclerosis (P = 0.033) were then demonstrated to be significant
prognostic factors of DPGN. The results suggest that intraglomerular
monocyte infiltration has a protective effect and confirm that Al index
is a relatively powerful predictor of outcome. Histologic and
nonhistologic biopsy factors contribute significant additional prognostic
information to that provided by Sc1..
Because of its relative severity, diffuse proliferative glomer-
ulonephritis (DPGN) is the most important form of renal disease
complicating systemic lupus erythematosus (SLE) [1—4]. This
form of glomerular disease has a widely variable course [1, 5—7]
and this has prompted a search for clinical and pathological
factors that would enable better prognostication and manage-
ment of the disease [5—16]. Although much attention has been
paid to the assessment of the prognostic value of histological
factors [6—8, 14, 16], there have been a number of studies that
have investigated nonhistological (ultrastructural, immunopath-
ological and histochemical) biopsy parameters [5, 6, 9, 11, 15,
16]. Most studies have included all classes of lupus nephritis [8,
9, 11, 14—16] but a few have been restricted to DPGN alone
[5—7].
Recently the histologically-determined biopsy parameters,
activity index (Al) and chronicity index (CI), have been shown
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to be of prognostic significance in DPGN [6, 7], but no attempt
was made to see whether these variables improved the prog-
nostic performance of clinical and/or clinical laboratory factors
demonstrated to be significant predictors of outcome. The
results of another study of DPGN indicated that the extent of
extraglomerular (tubulo-interstitial) deposits (EGD) was a valu-
able prognostic indicator and that it did increase the predictive
power of serum creatinine (Scr), also shown to be of prognostic
significance [5]. In this study a number of other histological and
nonhistological parameters, such as pathology index (P1 = A! +
CI), extent of total glomerular and subendothelial deposits, and
extent of intraglomerular monocytic infiltration, did not prove
to be of prognostic value, although the latter did significantly
improve the predictive power of Sf1..
To evaluate the prognostic value of both histological and
nonhistological biopsy parameters in DPGN, a comprehensive
study of 45 patients (35 of whom were the subject of a previous
report [5]) was performed. Proportional hazards analysis [17]
was used to evaluate the individual and combined effect of
explanatory variables on renal survival.
Methods
For the purpose of this study, all patients had to: 1) fulfill the
American Rheumatism Association criteria for the diagnosis of
SLE [18]; 2) be followed until death or established renal failure
(Scr  2.0 mg/dl on two or more separate occasions at least 3
months apart), or for a minimum of 6 months; 3) have sufficient
tissue for histological (minimum of 10 glomeruli), immunohis-
tochemical and histochemical evaluation; and 4) have a tissue
diagnosis of DPGN (Class IV) according to the WHO classifi-
cation of lupus nephritis [19]. In this class, more than 50% of
glomeruli show endocapillary proliferation whereas in the focal
lupus nephritis (WHO Class III) less than 50% of glomeruli
demonstrate this change.
Histology
Renal biopsy specimens were initially divided into three
portions for histology, electron microscopy and direct immu-
nofluorescence. For histology the tissue was fixed either in
Karnovsky's fixative (glutaraldehyde-formalin) or 2.5% buff-
ered glutaraldehyde and embedded in polyglycol methacrylate
(Polysciences Inc., Warrington, Pennsylvania, USA). One ml-
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cron sections were stained with hematoxylin-eosin (H-E) and
periodic acid-silver methenamine (PASM).
Direct immunofluorescence
Tissue was snap-frozen in liquid nitrogen-cooled isopentane.
Six micron sections were cut on a cryostat, stained with
commercially obtained fluoroscein-conjugated monospecific an-
tisera to human IgG, 1gM, IgA, Clq, C4, C3 and fibrin (Behring
Diagnostics, Montreal, P.Q.) and examined under ultraviolet
light. The proportion of the interstitium containing deposits of
immunoglobulin(s) with or without complement was estimated
and expressed as a percent.
Histochemistry
The presence of monocytes/macrophages in tissue was de-
tected using the alpha-naphthyl acetate stain for nonspecific
esterase (NSE). This was done on snap-frozen tissue sectioned
at 6 microns by the method of Yam, Lee and Crosby [201. The
NSE index in each case was the mean number of intraglomer-
ular cells showing strong diffuse cytoplasmic staining for NSE
per glomerular cross-section.
Activity and chronicity indices
The activity and chronicity indices were determined accord-
ing to the procedure detailed by Austin et al [61. Briefly, the
following histological features were scored on a scale from 0 to
3. The parameters evaluated included: 1) glomerular cell prolif-
eration; 2) leukocyte exudation; 3) karyorrhexis and/or fibrinoid
necrosis; 4) cellular crescents; 5) hyaline deposits; 6) interstitial
inflammation; 7) glomerular sclerosis; 8) fibrous crescents; 9)
tubular atrophy; and 10) interstitial fibrosis. To maintain inter-
study consistency, the assigned scores for cellular crescents
and karyorrhexis/fibrinoid necrosis were doubled because these
lesions are considered to be disproportionately severe [6, 14].
The activity index (Al) is the sum of the individual scores of the
following items considered to indicate activity: glomerular
proliferation; leukocyte exudation; karyorrhexis and/or fibri-
noid necrosis (X2); cellular crescents (X2); hyaline deposits;
and interstitial inflammation. It has a maximum value of 24. It
should be noted that using an A! in which the scores for active
crescents and fibrinoid necrosis/karyorrhexis were not doubled
yielded the same renal survival results as those obtained with
the traditionally calculated A!. The chronicity index (CI) is the
sum of the individual scores of those items indicating chronic
irreversible disease: glomerular sclerosis; fibrous crescents;
tubular atrophy; and interstitial fibrosis. The maximum CI is 12.
Statistical methods
The Cox proportional hazards model (17, 211 was used to
determine the individual and combined effects of prognostic
factors on 24 months, 60 months and ultimate renal (109
months, time of last failure in the study group) survival.
Survival times were measured from the time of biopsy. Creat-
mine was coded as a binary variable with a value of 0 indicating
that Scr was within normal limits ( 1.4 mg/dl) and a value of 1
indicating that it was not (Scr> 1.4 mg/dl), Nominal values for
all other variables were used. The effect of Al was analyzed
both with the scores for cellular crescents and karyorrhexis/
fibrinoid necrosis as recorded and doubled for reasons dis-
cussed above. Separate analyses were used to determine the
prognostic value of Al and CI and their components. Factor
analysis [22] was used to select a representative subset of the
component variables of A! and CI for subsequent analysis with
the proportional hazards model.
The assumption of proportionality of hazards for several of
the prognostic variables was assessed by inspection of log
minus log survival curve plots. P-values and confidence inter-
vals were calculated using the asymptotic normality of the
proportional hazards model parameter estimates. Calculations
were carried out using the BMDP program P2L [231 and SAS
PROC FACTOR [24].
The data was also analyzed using the life table method [251.
Results
General clinical and laboratory findings
Forty-five patients, 43 females and 2 males, with a mean age
of 26.0 years, were studied. The mean S1. at the time of biopsy
was 1.5 mg/dl and the number of patients with an abnormal SCr
(> 1.4 mg/dl) was 14. Seven patients (15%) had a Se,.  2.0
mg/dl at the time of biopsy. All patients had proteinuria and 30
(67%) of them had a nephrotic range of urinary protein excre-
tion (> 3.5 g/24 hr). The mean 24-hour urinary protein was 5.7
g. Thirty-seven patients had hematuria and 20 were hyperten-
sive (mild to moderate) at the time of biopsy. Twenty-nine
patients were on varying, but small, doses of prednisone at the
time of biopsy.
All but one patient received prednisone. Doses varied be-
tween 20 and 200 mg every other day. One patient was
prescribed prednisone but did not comply. Thirty-seven pa-
tients were treated with immunosuppressive drugs (azathio-
prine or cyclophosphamide) in addition to steroids. Definitive
treatment of the nephritis with high (or increased) dose steroid,
with or without immunosuppressives, was begun after biopsy.
For statistical purposes the end point was considered to be
established renal insufficiency defined as a Scr  2.0 mg/dl on
two or more occasions at least three months apart. For survival
analysis purposes, those patients with a S. 2.0 mg/dl at the
time of biopsy and at three months post-biopsy were considered
to have developed established renal insufficiency at three
months post-biopsy. The mean interval between biopsy and the
last follow-up visit, death or development of established renal
failure for the group was 44.9 months (range, 2 to 132 months).
The last renal failure occurred at 109 months post-biopsy. The
mean interval between the clinical diagnosis of renal disease
and last follow-up visit, death or the development of established
renal failure was 56.7 months (range, 2 to 204 months). Six
patients (13%), all women, died. The causes of death were
sepsis, cerebral hemorrhage, pulmonary edema, cerebral arte-
ntis and adenocarcinoma of the stomach (linitis plastica). In one
case the cause of death was unknown. Fourteen patients (31%)
developed established renal failure, six (13%) of whom required
chronic dialysis. Sixteen patients showed significant deteriora-
tion of renal function, defined as a 25% or more decrease in
creatinine clearance (Car), or if a repeat Ccr was not done, an
increase in SCr of 0.4 mg/dl or more between the biopsy and the
last visit. The cumulative renal survival (not being in estab-
lished renal failure) rates for the whole group at 24, 60 and 109
months were 0.78, 0.69 and 0.42.
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Table 1. Effect of various clinical laboratory and biopsy factorsa on renal survival at 24 months and over the entire study period
Parameter
Interquartile
range
24 Months Entire study period
Relative
hazard
95% Confidence
interval Pvalueb
Relative
hazard
95% Confidence
interval Pvalueb
Creatinine 09_1•6d 8.02 0.84—76.17 0.070 14.91 2.49—89.15 0.003
Urinary protein 2.8—7.5 0.98 0.71—1.36 0.924 0.97 0.79—1.18 0.770
Extraglomerular deposits (EGD) 0—20 1.02 0.99—1.06 0.130 1.02 0.79—1.05 0.152
NSE index 0.7—3.7 0.58 0.30—1.13 0.109 0.61 0.39—0.97 0.038
Activity index (AI)C 5—10 1.41 1.07—1.89 0.015 1.36 1.10—1.70 0.005
Chronicity index (CI) 0—3 1.17 0.87—1.57 0.292 1.15 0.87—1.52 0.316
Prednisone dosee 6—120 1.00 0.98—1.03 0.783 1.00 0.99—1.02 0.614
Immunosuppressive dosee 100—150 1.01 0.98—1.03 0.671 1.01 0.83—1.23 0.212
a The components of activity and chronicity indices (Al and CI) not included in evaluationb P-value based on asymptotic normality of coefficient/standard error
Activity index computed with doubled scores for karyorrhexis and crescentsd Interquartile range for raw measurements. For purposes of analysis Sr was treated as a binary variable.a Initial dose after biopsy
Relative hazards derived from proportional hazards model. A value greater than I indicates that increased levels of this factor decrease the
probability of survival while a value less than I indicates the reverse effect.
Of the seven patients who had a Scr  2.0 mg/dl at the time
of biopsy, five developed established renal insufficiency. One of
these patients required hemodialysis and three of them died.
Two patients showed significant renal functional improvement
and had SCr'S less than 2.0 mg/dl at time of the last follow-up
visit at 13 and 52 months.
General pathological findings
The number of viable glomeruli per biopsy varied from 10 to
56. The number of obsolete glomeruli per biopsy was generally
low. Twenty biopsies demonstrated obsolete glomeruli. In three
of these the percent obsolete glomeruli was between 25 and 50%
(grade 2). In seventeen the glomerular sclerosis score was 1
(less than 25% of glomeruli showing focal or global sclerosis).
Crescentic glomerulonephritis (cellular crescents in greater
than 50% of glomeruli) was diagnosed in two cases. In an
additional eight biopsies cellular crescents were noted in be-
tween 25 and 50% of glomeruli. Karyorrhexis/fibrinoid necrosis
was present in 21 biopsies. This change was generally very
focal. Extensive angiltis was present in two biopsies. Extraglo-
merular (tubulo-interstitial) immune complex deposits were
present in 32 (71%) of the biopsies. They were relatively
extensive (present in 50% or more of the interstitium) in seven
cases and moderately so (20 to 50%) in an additional ten
patients. Some degree of intraglomerular monocyte infiltration
was noted in 40 biopsies. This was moderate to marked (NSE
index > 3) in 13 cases.
The median (and mean) scores for Al, CI, EGD and NSE
index were as follows: A! = 8(8), CI 2(1.9), EGD (expressed
as an estimated percent of the interstitium in which immune
deposits containing immunoglobulin(s) with or without comple-
ment were seen) = 10 (19.2) and NSE index = 1.8 (2.5).
Five patients had repeat biopsies, three with one repeat and
two with two. The indications for repeat biopsies were deteri-
orating renal function in four cases and relapse of active renal
disease in a young woman. In two of the cases relatively
extensive angiitis was a new development. In all cases the A! of
the repeat biopsies was lower than the Al of the first one, and
the CI had increased. Cl's of 5 or more were demonstrated in
0.0 - -
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Fig. 1. Probability of renal survival for normal and elevated serum
creatinines based on model in Table 1. All other variables are at their
means. Month = 0 is the time of the renal biopsy. Symbols are: (—.)
creatinine
 1.4; ( ) creatinine > 1.4.
five out of the seven repeat biopsies (in four of the patients) but
in only two of the 47 first biopsies. The four patients with a CI
of 5 or more on repeat renal biopsies developed established
renal failure.
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Evaluation of clinical and biopsy parameters for prognostic
significance
The following parameters were assessed for prognostic sig-
nificance: Scr (previously shown to be a significant predictor
[51), 24-hour tginary protein excretion, Al and its individual
components, glomerular cell proliferation, leukocyte exuda-
tion, karyorrhexis/fibrinoid necrosis, active crescents, hyaline
deposits and interstitial inflammation, CI and its individual
components, glomerular scletosis, fibrous crescents, tubular
atrophy and interstitial fibrosis, EGD and NSE index. Because
ot the possibility that treatment may have affected outcome in
this study, the initial dose of steroid and immunosuppressive
were included as variables in the analysis.
Table 1 gives the results of the proportional hazards analysis
of renal survival at 24 months and over the entire study period
with Al and Cl included ahiong the explanatory variables.
Results for 60-month renal survival were almost identical to
those for ultimate survival and are not included. With respect to
24 month survival, only A! (either weighted or unweighted) had
a significant effect (P = 0.015) when all other variables were
taken into account. Its effect can be interpreted as follows. An
increase of A! by I unit decreased the probability of survival by
an exponential factor of 1.41, given that all other covariates
remain fixed. That is, if the probability of survival to 24 months
at some level of the covariates was 0.90, then, if the Al
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>
C
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a
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increased by 1 unit and all other covariates remained the same,
the probability of survival would be 0.90'' = 0.86; if Al
increased by 2 units, the probability of renal survival would
decrease to 0.901 = 0.81 (where 1.99 = 1.412).
In terms of renal survival throughout the entire study period,
creatinine level at biopsy (P = 0.003), A! (P = O.005) and to a
lesser extent NSF index (P = 0.038) had significant effects on
renal survival when all the other factors in Table 1 are taken
into account. The effect of 5cr on renal survival is depicted in
Figure 1, where it is shown that abnormal SCr levels (> 1.4
mg/dl) greatly increase the probability of renal failure at any
given time. Similarly, the effects of Al and NSE index on renal
survival with Sc either  1.4 mg/dl or> 1.4 mg/dl are depicted
in Figures 2 and 3.
Proportional hazards analysis based on all of the components
of Al and CI was inappropriate because of collinearity, that is,
the components were highly correlated. Because of this, the
confidence intervals for the relative hazards were extremely
wide and the algorithm used in the program BMDP P2L did not
obtain estimates for 24 month and 60 thonth survival. To
remedy this, factor analysis was used to obtain a subset of these
measurements which captured much of the variability in the
original data. The variables chosen to be representative of A!
and CI for subsequent analysis were crescents, karyorrhexis
and glomerular sclerosis.
Results of this analysis are reported in Table 2. It shows that
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Fig. 2. Probability of renal survival for activity indices (Al) at the 25th ( Al = 5) and 75th (—Al = 10) percentiles based on model in Table
1. A. Serum creatinine (Scr) 1.4 mg/dl. B. Scr> 1.4 mg/dl. All other variables are at their means, Month = 0 is the time of the biopsy.
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Table 2. Effect of clinical laboratory and biopsy factors including the components of activity and chronicity indicesa on renal survival at 24
months and over the entire study period
Interquartile
24 Months Entire study period
Relative 95% Confidence Relative 95% Confidence
Parameter range hazard interval Pvalueb hazard interval Pvalueb
Serum creatinine 0.9_l.6c 17.54 1.11—278.12 0.042 36.32 4.80—275.09 0.0005
Urinary protein 2.8—7.5 1.12 0.77—1.63 0.540 1.02 0.79—1.32 0.892
Extraglomerular deposits (EGD) 0—20 1.06 1.00—1.12 0.051 1.04 1.00—1.07 0.057
NSE index 0.7—3.7 0.37 0.12—1.14 0.084 0.56 0.34—0.94 0.024
Crescents 0—2 1.58 0.83—3.01 0.168 1.29 0.83—2.02 0.252
Karyorrhexis 0—2 4.36 1.29—14.70 0.017 2.53 1.62—3.94 0.035
Glomerulosclerosis 0—1 5.79 0.91—36.88 0.063 3.33 1.10—10.04 0.033
Prednisone dosed 60—120 0.99 0.97—1.02 0.695 1.00 0.98—1.02 0.984
Immunosuppressive dosed 100—150 1.02 0.98—1.06 0.272 1.02 1.00—1.05 0.075
a Activity and chronicity indices (A! and CI) not included in evaluation
b P-value based on asymptotic normality of coefficient/standard error
Interquartile range for raw S. measurements. For purposes of analysis Scr was treated as a binary variable.
d Initial dose after biopsy
e Relative hazards derived from proportional hazards model. A value greater than I indicates that increased levels of this factor decrease the
probability of survival while a value less than I indicates the reverse effect.
for 24-month renal survival, when taking the other measure- significant variable, while NSE index (P =0.024), karyorrhexis
ments into account, karyorrhexis was the most significant (P = 0.035) and glomerular sclerosis (P = 0.033) had lesser
measurement (P = 0.017), while creatinine (P = 0.042) and effects. Results for 60-month survival are almost identical to
EGD (P = 0.051) had lesser effects. In terms of survival that for survival throughout the study period and are not
throughout the study period, (P = 0.0005) was the most reported.
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Fig. 3. Probability of renal survival for NSE indices at the 25th (—NSE index = 0.7) and the 75th ( NSE index = 3.7) percentiles based on
model in Table 1. A. Serum creatinine (Sr)  1.4 mg/dl. B. Sf1> 1.4 mg/dl. All other variables are at their means. Month = 0 is the time of the
biopsy.
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We observed that, with the exception of NSE index, all
significant variables had relative hazards greater than 1. This
means that increased levels of these quantities decreased the
probability of renal survival, For NSE index, the relative
hazard was less than 1 implying that elevated levels of NSE
index increased the probability of renal survival (Fig. 3).
In all analyses, the effects of initial steroid and immunosup-
pressive drug dose were insignificant. Inasmuch as this is a
retrospective study, the data on cumulative steroid dose is
incomplete and the effect of this variable on renal survival was
not evaluated. Thus, we cannot exclude the possibility that the
cumulative steroid dose had a significant influence on outcome.
Discussion
The present study represents both a modification and exten-
sion of a previous one of the same subject reported in 1984 [5].
In that it is confined only to patients with DPGN (including the
membranoproliferative type), it is similar to two other investi-
gations that have been reported recently 16, 71. This restriction
permits the study of a pathologically more homogeneous group
of patients and avoids the biases that may possibly result in
some misleading conclusions about DPGN, particularly when
all classes of lupus nephritis are considered together. An
example of this is the extent of subendothelial deposits which
was shown to be of prognostic importance in two studies which
included all classes of lupus nephritis [9, 26], but of no signifi-
cance when only DPGN was investigated [5].
The present study, while similar in approach to studies of
DPGN from other institutions 16, 7], differs from them in
several important respects. Unlike the latter, the present inves-
tigation and a previous one from our laboratory [5] were not
confined to biopsy factors alone but did include an assessment
of some clinical laboratory parameters. Moreover, nonhistolog-
ically, immunopathologically and histochemically determined
variables were also assessed. Whereas end-stage renal disease
was used as the end point in one study [61, established renal
insufficiency (Sc,.  2.0 mg/dl on 2 or more occasions at least 3
months apart) served this function in the present investigation.
Proportional hazards analysis which assesses the simultaneous
influence of a number of independent variables on outcome [171
was used in this study. It should be noted that a similar
approach to ours was used in one study that included all classes
of lupus nephritis [8].
A! has been shown to be a significant predictor of outcome in
lupus nephritis in some studies 16, 8, 271 but not in others [7]. In
the previous investigation of DPUN reported by our group, the
value of A! was not assessed [5]. The results of the present
study confirm that Al is a significant prognostic factor. More-
over it appears that Al contributes significant additional infor-
mation to that provided by Scr alone in agreement with a
previous study that included all classes of lupus nephritis [8].
The observation of tubular basement membrane lesions as-
sociated with the presence of EGD alone [28] and the presence
of the membrane attack complex in them [291 suggest both a
role for these deposits in the progression of renal disease in
SLE and a possible value for them as a predictor of outcome.
The results of the present study indicated that the extent of
EGD has at best only marginal value as a prognostic factor in
contrast to a previous evaluation where this parameter was
shown to be significant [5]. This discrepancy can be explained
by the difference in statistical analysis between the two studies.
In the previous one [5], each parameter was evaluated individ-
ually by life table analysis, whereas in the present one, propor-
tional hazards analysis which evaluates the individual and
combined effect of several variables on outcome was used. The
results suggest some degree of interrelationship between the
extent of EGD and one or more other variables.
Intraglomerular monocyte infiltration has been demonstrated
in a number of human and experimental glomerulonephritides
[30—38] including SLE [5, 30, 32, 39], and the results of some
studies indicate that these cells may mediate glomerular damage
[36, 38, 391. The results of the present study are at variance with
this in that they suggest that prominent intraglomerular mono-
cyte infiltration has a protective effect. A number of investiga-
tions have suggested that monocytes are involved in the clear-
ance of immune deposits in glomeruli [32, 33, 37, 40—431. This
may account for the observed association of a relatively high
NSE index with good prognosis since persistence of subendo-
thelial deposits has been shown to be related to a poor outcome
in lupus nephritis [44].
Evaluation of the components of Al and CI demonstrated
that the extent of karyorrhexis and glomerulosclerosis were
significant predictors of outcome. As the determination of A! is
laborious, the substitution of glomerulosclerosis and karyor-
rhexis scores for Al in the assessment of prognosis would
appear worthwhile if it could be shown that the combination of
these two components has the equivalent predictive power of
A!. Unfortunately this was not done as it was outside the scope
of the present study.
The present investigation failed to confirm CI on first biopsy
as a significant predictor of outcome as had two previous
studies [6, 7]. However, in four of the five patients who had
repeat biopsies, a high CI (> 4) was present and renal failure
developed in all of them, suggesting that the CI in repeat
biopsies may be of prognostic significance. This is similar to the
experience of one group which reported that CI determined on
entry biopsy was not a significant predictor of outcome but on
repeat biopsies was [27]. Comparison of the relevant biopsy
data from the present study with that of two previous ones,
which demonstrated prognostic significance for CI in DPGN [6,
7], reveals that in both of the latter there were proportionately
more patients with a high CI than in the present one and this
may account for the discrepancy in the results.
In conclusion, the present study has demonstrated that the
prognosis in DPGN is influenced by several biopsy-determined
histological and nonhistological factors which contribute signif-
icant independent prognostic information when the clinical
determined factor, Sr, is taken into account and supports the
value of performing renal biopsies in diffuse lupus nephritis.
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